TREM2 and colorectal carcinoma: Intriguingly, several groups have demonstrated that the abrogation of TREM2 activity in mice, by Trem2 KO models or by Trem2 antibody-based blocked therapies, induced tumor growth delay and synergistic effect on T cell restoration functions concomitantly with anti-PD-1 blockade in many mouse models (CRC, sarcoma) (28).